Alimera Sciences

6120 Windward Pkwy, Alpharetta, March 2017

Alimera Sciences is a biopharmaceutical company focused on the research, development, and commercialization of prescription ophthalmology treatments. Founded in 2003, Alimera Sciences has dedicated itself to addressing the needs of patients suffering from retinal diseases, a category of eye diseases that can lead to severe vision impairment or blindness. The company's flagship product, ILUVIEN, is an intravitreal implant designed to treat diabetic macular edema (DME), a condition that can result from diabetes.

History

Alimera Sciences was established with the goal of providing innovative treatments for retinal diseases. Over the years, the company has grown significantly, focusing its efforts on developing therapies that can offer long-term benefits to patients with few treatment options. The development and approval of ILUVIEN have been pivotal milestones in the company's history, marking its success in bringing a novel treatment to market.

ILUVIEN

ILUVIEN is an extended-release intravitreal implant used to treat diabetic macular edema, a complication of diabetes that affects the macula and can lead to vision loss. The implant is designed to release a low dose of fluocinolone acetonide, a corticosteroid, over a period of up to 36 months. This slow-release mechanism helps to reduce the swelling of the macula, offering a long-term treatment solution for patients with DME.

Research and Development

Alimera Sciences is actively involved in research and development to expand its portfolio of retinal disease treatments. The company's R&D efforts are focused on identifying new therapeutic targets and developing innovative drug delivery systems that can improve the quality of life for patients with retinal diseases.

Market and Distribution

Since its launch, ILUVIEN has been approved in multiple countries, including the United States, several European countries, and the United Arab Emirates. Alimera Sciences has established a strong presence in the global ophthalmology market, working closely with healthcare professionals and patients to ensure access to its treatments.

Corporate Responsibility

Alimera Sciences is committed to corporate responsibility, with initiatives aimed at improving patient care, supporting communities, and ensuring ethical business practices. The company's patient assistance programs are designed to help those in need access their treatments, reflecting Alimera's dedication to making a positive impact on society.

Future Directions

Looking forward, Alimera Sciences aims to continue its growth and innovation in the field of ophthalmology. The company is exploring new indications for ILUVIEN and other potential treatments to address a broader range of retinal diseases. With a strong foundation in research and a commitment to patient care, Alimera Sciences is poised to remain a key player in the development of ophthalmic treatments.